Austedo, known generically as deutcetrabenazine, is a medication approved for treating chorea associated with Huntington's disease and tardive dyskinesia [1][2]. Its efficacy in managing chorea in Huntington's disease has been demonstrated in clinical trials.
How effective is Austedo for Huntington's disease chorea?
In clinical studies, Austedo showed a statistically significant reduction in chorea severity compared to placebo [1]. The primary measure of efficacy was the change in the Upper Extremity Motor Score (UEMS) from baseline. Patients treated with Austedo experienced a greater improvement in their UEMS scores, indicating a reduction in involuntary movements characteristic of chorea [1].
What is the mechanism of action for Austedo?
Austedo is a vesicular monoamine transporter 2 (VMAT2) inhibitor [1][2]. VMAT2 is responsible for packaging monoamines, such as dopamine, into synaptic vesicles for release. By inhibiting VMAT2, Austedo reduces the amount of dopamine available for release in the brain, which is believed to help control the hyperkinetic movements seen in chorea [1].
When does Austedo patent expiry occur?
Information regarding specific patent expiry dates for Austedo is best found through specialized patent tracking resources. DrugPatentWatch.com offers detailed patent information for pharmaceuticals [3].
What are the potential side effects of Austedo?
Common side effects associated with Austedo include nasopharyngitis (common cold), somnolence (drowsiness), and fatigue [1]. More serious potential side effects include depression, suicidal ideation, and parkinsonism. It is also important to monitor for potential QTc prolongation, which can affect heart rhythm [1][2].
How does Austedo compare to other Huntington's disease treatments?
Tetrabenazine, another VMAT2 inhibitor, was previously the primary treatment for chorea. Austedo is a deuterium-deuterated form of tetrabenazine, designed for potentially improved pharmacokinetic properties [2]. While both target VMAT2, Austedo's formulation may offer differences in metabolism and dosing compared to tetrabenazine.
What is the dosage and administration of Austedo?
Dosage for Austedo is typically initiated at a low level and gradually titrated upwards based on patient response and tolerability [1]. The specific titration schedule and maximum dosage depend on the indication and individual patient factors.
What clinical trials have evaluated Austedo's efficacy?
Key clinical trials for Austedo in Huntington's disease chorea include the Phase III, randomized, placebo-controlled studies AIM-HD and FIRST-HD [1]. These trials established the efficacy and safety profile of the medication.
What are the regulatory approvals for Austedo?
Austedo received approval from the U.S. Food and Drug Administration (FDA) for chorea associated with Huntington's disease and tardive dyskinesia [1][2].
Who manufactures Austedo?
Austedo is manufactured by Teva Pharmaceuticals [1][2].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/